Neurocrine Expands Rare Disease Portfolio with $2.9B Soleno Buy
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.
/ 60 items
#XY News-Driven Stocks↓
FDA Tightens Rules on Copycat Ozempic and Wegovy – No More Routine Compounding
FDA limits copycat GLP-1 drugs; pharmacies can only make them during shortages. Original meds like Foundayo now safer & more available.
FDA Delays Popular Nicotine Pouches Over Youth Risks
Popular nicotine pouches like Zyn and Velo remain unapproved in the US despite FDA fast-track. Agency hesitates due to rising youth use and addiction concerns.
Why Merck’s Big CML Bet Makes Enliven’s ELVN-001 a Takeover Star
Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
Grifols Plans U.S. IPO for Biopharma Business to Cut Debt and Boost Growth
Grifols has approved a U.S. IPO of a minority stake in its Biopharma business.
Elliott Takes Big Stake in Invisalign Maker Align Technology to Boost Slumping Stock
Activist investor Elliott Investment Management takes major stake in Align Technology, Invisalign maker, to push for stock price gains amid post-pandemic slump.